Pharma — Juli 2023
-
Medicinalselskabets egen udmelding er, at forsøgsresultaterne gav "overbevisende beviser" for den potentielle fremtidige rolle, som lægemidlet kan spille i forhold til behandling af lungecancer.
De oplyser derudover, at det nye kræftmiddel er et bedre alternativ til Docetaxel, der i øjeblikket anses som værende standarden for kemoterapi. Det er dog ifølge selskabet stadig for tidligt, at bekræfte dette med statistiske belæg.
-
Analytikere hos finanshuset Citi er overordnet set positive overfor resultatet, men fortæller samtidig et det ikke nødvendigvis er det "home run", som investorerne håbede på.
Ken Takeshita, der er administrerende direktør og global leder af onkologisk forskning og udvikling hos Daiichi Sankyo, der samarbejder med Astrazeneca om udviklingen af lægemidlet, fortæller at virksomhederne planlægger at dele alle data med myndighederne for at diskutere de næste skridt.
-
.\˙ MarketWire
-
Moderna vil angiveligt investere op mod 1 mia. dollar i Kina https://www.proinvestor.com/investornyt/1009812/moderna-vil-angiveligt-investere-op-mod-1-mia-dollar-i-kina
-
FDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's Disease https://www.proinvestor.com/investornyt/1011364/fda-grants-traditional-approval-to-eisais-leqembi-to-treat-adult-patients-with-alzheimers-disease
-
2 Reasons to Buy Johnson & Johnson, and 1 Reason to Sell https://www.proinvestor.com/investornyt/1011475/2-reasons-to-buy-johnson-amp-johnson-and-1-reason-to-sell
-
HC Wainwright & Co. Reiterates ASLAN Pharmaceuticals Ltd - ADR (ASLN) Buy Recommendation https://www.proinvestor.com/investornyt/1011989/hc-wainwright-amp-co-reiterates-aslan-pharmaceuticals-ltd-adr-asln-buy-recommendation
-
Why Novartis Stock Slipped on Friday https://www.proinvestor.com/investornyt/1011988/why-novartis-stock-slipped-on-friday
-
Lundbeck får løftet kursmål med 5 kr. hos finanshuset Citi
10.7.2023 06.44 • MarketWire •
Lundbeck har fået løftet kursmålet for aktien til 35 kr. fra 30 kr. hos finanshuset Citi.Det fremgår af Bloomberg News.
Anbefalingen "neutral" gentages.
Lundbeck-aktien lukkede fredag i 31,70 kr. efter et fald på 0,5 pct.
.\˙ MarketWire
-
Pfizer og Moderna opfordres til rimelig
prissætning af tilpasset covid-vaccine https://www.proinvestor.com/investornyt/1014492/pfizer-og-moderna-opfordres-til-rimelig-prissaetning-af-tilpasset-covid-vaccine -
Johnson & Johnson Poised For A Muted Q2? https://www.proinvestor.com/investornyt/1015967/johnson-amp-johnson-poised-for-a-muted-q2
-
New Alzheimer’s Drug Is First to Show It Slows Disease. But It’s Facing a Rocky Rollout https://firstwordpharma.com/story/5761407
-
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In. https://firstwordpharma.com/story/5761397
-
Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here’s What To Expect
17/7 10:18
In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide. https://www.proinvestor.com/investornyt/1016000/acadia-pharmaceuticals-rights-deal-and-bullish-outlook-sends-shares-surging-16-heres-what-to-expect
-
Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock? https://www.proinvestor.com/investornyt/1015999/acadia-acad-soars-247-is-further-upside-left-in-the-stock
-
Eli Lilly med positivt resulat af Alzheimers-forsøg https://www.proinvestor.com/investornyt/1016270/eli-lilly-med-positivt-resulat-af-alzheimers-forsog
-
Schweizisk Genmab-partner opjusterer efter overbevisende kvartal https://www.proinvestor.com/investornyt/1016615/schweizisk-genmab-partner-opjusterer-efter-overbevisende-kvartal
-
Cantor Fitzgerald Reiterates Lilly (LLY) Overweight Recommendation https://www.proinvestor.com/investornyt/1016612/cantor-fitzgerald-reiterates-lilly-lly-overweight-recommendation
-
Lilly Says Its Alzheimer's Drug Significantly Slowed Cognitive And Functional Decline https://www.proinvestor.com/investornyt/1016637/lilly-says-its-alzheimers-drug-significantly-slowed-cognitive-and-functional-decline
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind